Items where authors include "Kakkar, V."

Article

Di Donato, S. orcid.org/0000-0003-1256-0761, Ross, R., Karanth, R. et al. (7 more authors) (2025) Serum Type I Interferon Score predicts clinically meaningful disease progression in limited cutaneous Systemic Sclerosis. Arthritis & Rheumatology. ISSN 2326-5191

Roth, E., Bruni, C., Petelytska, L. et al. (244 more authors) (2025) Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort. Rheumatology. keaf016. ISSN 1462-0324

Ross, R.L., Caballero-Ruiz, B., Clarke, E.L. et al. (11 more authors) (2024) Biological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of SSc (VEDOSS). Rheumatology. keae698. ISSN 1462-0324

De Lorenzis, E., Natalello, G., Pellegrino, G. et al. (29 more authors) (2024) Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life. Rheumatology. keae532. ISSN 1462-0324

De Lorenzis, E., Del Galdo, F., Natalello, G. et al. (10 more authors) (2024) Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression. American Journal of Respiratory and Critical Care Medicine. ISSN 1073-449X

Wasson, C., Dibb, S., Bryon, J. et al. (8 more authors) (2024) P27 Chloride intracellular channel 4 is a global regulator of type 1 interferon signalling in systemic sclerosis skin. British Journal of Dermatology, 190 (6). e91-e92. ISSN 0007-0963

De Lorenzis, E. orcid.org/0000-0001-9819-105X, Kakkar, V., Di Donato, S. et al. (13 more authors) (2024) Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets. RMD Open, 10 (1). e003216. ISSN 2056-5933

Kakkar, V., Assassi, S., Allanore, Y. et al. (4 more authors) (2022) Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Current Opinion in Rheumatology, 34 (6). pp. 357-364. ISSN 1040-8711

Conference or Workshop Item

Colak, S.Y., Di Donato, S., Bixio, R. et al. (6 more authors) (2025) POS0497 12 months sensitivity to change and clinical important differences of EULAR ScleroID: a comprehensive pro measuring impact of systemic sclerosis on how patients feel and function. In: EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain.

DI Donato, S., Ross, R., Karanth, R. et al. (6 more authors) (2024) OP0314 Interferon score as a novel trial enrichment tool to predict clinical outcomes in patients with limited cutaneous systemic sclerosis. In: EULAR 2024 European Congress of Rheumatology, 12-15 Jun 2024, Vienna, Austria.

De Lorenzis, E., Natalello, G., Di Donato, S. et al. (6 more authors) (2023) AB0841 concordance and prognostic relevance of different definitions of systemic sclerosis interstitial lung disease progression. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

De Lorenzis, E., Kakkar, V., Di Donato, S. et al. (13 more authors) (2023) AB0881 clinical trajectories of multifactorial hand function deterioration in systemic sclerosis. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

Proceedings Paper

Colak, S.Y., Di Donato, S., Bixio, R. et al. (6 more authors) (2025) POS0497 12 MONTHS SENSITIVITY TO CHANGE AND CLINICAL IMPORTANT DIFFERENCES OF EULAR ScleroID: A COMPREHENSIVE PRO MEASURING IMPACT OF SYSTEMIC SCLEROSIS ON HOW PATIENTS FEEL AND FUNCTION. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier .

Kaye, E., Osborne, T., Thornton, L. et al. (4 more authors) (2025) POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. .

Kakkar, V., Kim, S., Bi, Y. et al. (7 more authors) (2025) ABS0025 GROWTH DIFFERENTIATION FACTOR 15 IS A SERUM BIOMARKER AND PATHOGENIC FACTOR OF PROGRESSIVE FIBROSIS IN SYSTEMIC SCLEROSIS. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , p. 2264.

Kakkar, V., Kim, S., Bi, Y. et al. (7 more authors) (2025) Growth Differentiation Factor 15 is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. BMJ Publishing Group , p. 2264.

Teenan, O., Ross, R., Steer, I. et al. (4 more authors) (2025) OP0012 SomaScan proteomic analysis of the skin across the Systemic Sclerosis (SSc) disease continuum reveals a distinct very early-specific profile vs a fibrotic profile. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. BMJ Publishing Group , pp. 11-12.

Teenan, O., Ross, R., Steer, I. et al. (4 more authors) (2025) OP0012 SomaScan proteomic analysis of the skin across the Systemic Sclerosis (SSc) disease continuum reveals a distinct very early-specific profile vs a fibrotic profile. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , pp. 11-12.

Bamigbola, I.E., Vadakekolathu, J., Di Donato, S. et al. (5 more authors) (2025) OP0215 SPATIAL TRANSCRIPTOMICS OF SKIN BIOPSIES FROM VERY EARLY SYSTEMIC SCLEROSIS UNVEILS EARLY DRIVERS OF SKIN FIBROSIS WITHIN THE EPIDERMIS. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , p. 179.

Kaye, E., Osborne, T., Thornton, L. et al. (4 more authors) (2025) POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. BMJ Publishing Group , p. 730.

Di Donato, S., Hughes, M., Geloshi, K. et al. (6 more authors) (2023) P156 Evidence of Type I interferon activation during vascular manifestations of systemic sclerosis. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

De Lorenzis, E., Kakkar, V., Di Donato, S. et al. (4 more authors) (2023) P159 Clinical trajectories and predictors of hand function deterioration in systemic sclerosis. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

De Lorenzis, E., Kakkar, V., Ross, R. et al. (11 more authors) (2022) POS0876 Serum Interferon Score Predicts Severity Of Patient Reported Hand Disability In Systemic Sclerosis. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 733-734.